Sanofi’s Revenue Growth in 2Q17

Sanofi’s revenue in 2Q17 At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. Structure of the group The above chart shows Sanofi’s segment-wise revenue over the last few quarters. In 2016, Sanofi reorganized itself into five business units: Sanofi […]

Mike Benson - Author
By

Aug. 17 2017, Updated 7:37 a.m. ET

uploads///Chart  SWR

Sanofi’s revenue in 2Q17

At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros.

Article continues below advertisement
Article continues below advertisement

Structure of the group

The above chart shows Sanofi’s segment-wise revenue over the last few quarters. In 2016, Sanofi reorganized itself into five business units:

  • Sanofi Genzyme, which represents the specialty care business, including oncology and rare disease drugs
  • General Medicines and Emerging Markets
  • Diabetes and Cardiovascular
  • Consumer Healthcare
  • Sanofi Pasteur, which represents the human vaccine business

The company also announced two changes in the group’s business structure on January 1, 2017:

  • Sanofi exchanged its animal health business, Merial, with Boehringer Ingelheim’s consumer healthcare business
  • Sanofi terminated its European vaccine joint venture with Merck and Co. (MRK), Sanofi Pasteur MSD 

At constant exchange rates, the company reported 0.6% revenue growth in 2Q17.

Segment-wise performance 2Q17

Sanofi’s business is reported in two segments:

  • the Pharmaceuticals segment, which comprises Sanofi Genzyme, Diabetes and Cardiovascular, General Medicines and Emerging Markets, and Consumer Healthcare
  • the Human Vaccines segment, which includes Sanofi Pasteur

The Pharmaceuticals segment’s revenue rose by 4.1% to 7.7 billion euros in 2Q17, compared with 7.4 billion euros in 2Q16. Sanofi Pasteur’s revenue rose by 27.5% to 1.0 billion euros in 2Q17, compared with 797 million euros in 2Q16. 

To divest company-specific risks, investors could consider the VanEck Vectors Pharmaceutical ETF (PPH) which has a 5.2% exposure to Sanofi. PPH also has a 5.6% exposure to Novo Nordisk (NVO), a 5.1% exposure to Merck and Co. (MRK), and a 4.9% exposure to Eli Lilly and Company (LLY).

Advertisement

Latest Novo Nordisk A/S News and Updates

    Opt-out of personalized ads

    © Copyright 2024 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.